Skip to content

Released Mar 16, 2020, before the open

10-K filed Mar 16, 2020, 76 days after period end · 0001564590-20-010998

Q4 2019 · 10-K
Revenue$696.00K−58.9% vs Q4 2018+304.7% vs Q3 2019
Net Income-$24.99MN/M vs Q4 2018N/M vs Q3 2019
EPS Diluted-$1.31N/M vs Q4 2018N/M vs Q3 2019
Operating Incomederived-$25,883,000N/M
Operating Cash Flowderived-$17,367,000N/M
Free Cash Flowderived-$17,496,000N/M
Margins · derived
Operating margin-3718.8%−3063.7 pt vs Q4 2018
Net margin-3589.9%−2963.5 pt vs Q4 2018

What the release said

The release

Same quarter

MetricQ4 2019Q4 2018Q4 2017Q4 2016
Revenue$696.00K$1.69M$993.00K—
Net Income-$24.99M-$10.60M-$13.86M-$7.21M
EPS Diluted-$1.31-$0.60-$1.59-$25.68

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR